- Full text PDF available (0)
- This year (0)
- Last 5 years (0)
- Last 10 years (0)
Journals and Conferences
Born 20 years ago with the launch of recombinant insulin, the biotechnology industry is maturing, with several leading companies now rivalling traditional pharmaceutical companies in many ways. What might the next 20 years hold for biotech-based drug development?
NATURE REVIEWS | DRUG DISCOVERY VOLUME 1 | NOVEMBER 2002 | 845 Twenty years ago, the commercial launch of recombinant insulin, the first biotechnologyderived drug, marked the birth of biotech. Today, biotech is coming into its own as a mature industry, although its growing pains are exacerbated by the current economic climate. Here, we take a look at how… (More)
Teriparatide (Forteo; Eli Lilly), a recombinant form of the 34 amino-terminal amino acids of human parathyroid hormone, was approved by the US FDA in November 2002 for the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just reduce bone loss, what impact is it likely to have on the osteoporosis drug market?